0.4004

5.61% -0.0238

After Hours: .41 0.0096 +2.40%

Klotho Neurosciences Inc (KLTO)

Overview News Price History Discussions Forecast

Klotho Neurosciences Inc stock is traded at $0.4004, with a volume of 935.27K. It is down -5.61% in the last 24 hours and down -22.33% over the past month. Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.

Previous Close:

$0.4242

Open:

$0.4371

24h Volume:

935.27K

Relative Volume:

0.67

Market Cap:

$29.04M

Revenue:

Net Income/Loss:

$-11.35M

P/E Ratio:

-0.8792

EPS:

-0.4554

Net Cash Flow:

$-5.51M

1W Performance:

-20.08%

1M Performance:

-22.33%

6M Performance:

-79.98%

1Y Performance:

-9.25%

1-Day Range:

$0.40

$0.4371

1-Week Range:

$0.40

$0.4894

52-Week Range:

$0.1135

$3.9099

Klotho Neurosciences Inc Stock (KLTO) Company Profile

Name

Klotho Neurosciences Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

(833) 931-6330

Address

13576 WALNUT STREET, SUITE A, OMAHA

Employee

Twitter

Next Earnings Date

Latest SEC Filings

KLTO's Discussions on Twitter

Compare KLTO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KLTO Klotho Neurosciences Inc	0.4004	30.77M	0	-11.35M	-5.51M	-0.4554
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Klotho Neurosciences Inc Stock (KLTO) Latest News

09:04 AM

What analysts say about Klotho Neurosciences Inc Equity Warrant stockMean Reversion Trades & High Yield Portfolio Picks - earlytimes.in

09:04 AM

Dec 08, 2025

Klotho Neurosciences enters agreement to sell Series C preferred stock to Sigma9 Capital - Investing.com Australia

Dec 08, 2025

Get in on Klotho Neurosciences Inc’s (KLTO) buy-in window today! - setenews.com

Dec 08, 2025

Dec 07, 2025

Klotho Neurosciences files to sell 35M shares of common stock for holders - MSN

Dec 07, 2025

EBITDA per share of Klotho Neurosciences, Inc. Warrant 2024-21.06.29 on Klotho Neuroscience – NASDAQ:KLTOW - TradingView

Dec 07, 2025

Dec 06, 2025

Is Klotho Neurosciences Inc Equity Warrant a good long term investmentFlag and Pennant Patterns & Low Entry Investment Growth - earlytimes.in

Dec 06, 2025

Dec 05, 2025

Why Klotho Neurosciences Inc. Equity Warrant stock could benefit from AI revolutionJuly 2025 Technicals & Free Long-Term Investment Growth Plans - Newser

Dec 05, 2025

Dec 03, 2025

Is Klotho Neurosciences Inc. Equity Warrant stock a safe buy before earnings2025 Breakouts & Breakdowns & Safe Entry Zone Identification - Newser

Dec 03, 2025

Dec 02, 2025

Does Klotho Neurosciences Inc. Equity Warrant stock trade at a discount to peersPortfolio Return Summary & AI Driven Stock Reports - Newser

Dec 02, 2025

Klotho Neurosciences (KLTO) Stock Analysis Report | Financials & Insights - Benzinga

Dec 02, 2025

Dec 01, 2025

Investors in cash trouble should check out Klotho Neurosciences Inc (KLTO) - setenews.com

Dec 01, 2025

Klotho Neurosciences, Inc. announced that it expects to receive $14.96 million in funding from Sigma9 Capital Ltd - marketscreener.com

Dec 01, 2025

Nov 30, 2025

Klotho Neurosciences, Inc. Warrant 2024-21.06.29 on Klotho Neuroscience - TradingView

Nov 30, 2025

Nov 29, 2025

Klotho Neurosciences Stock Skyrockets On Anti-Aging Gene Therapy Breakthrough: Retail Traders Over The Moon - MSN

Nov 29, 2025

Nov 27, 2025

Klotho Neurosciences (NASDAQ:KLTO) Trading Down 8.8% – What’s Next? - Defense World

Nov 27, 2025

Nov 26, 2025

Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market (PR Newswire) - Aktiellt

Nov 26, 2025

Nov 25, 2025

Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease") (PR Newswire) - Aktiellt

Nov 25, 2025

You might want to take a look at Klotho Neurosciences Inc (KLTO) now - Setenews

Nov 25, 2025

Nov 21, 2025

Is Klotho Neurosciences Inc a good long term investmentChart Pattern Recognition & Free Daily Investment Newsletter Subscription - earlytimes.in

Nov 21, 2025

Does Klotho Neurosciences Inc (KLTO) offer a good opportunity for investors? - Setenews

Nov 21, 2025

Nov 20, 2025

Klotho Neurosciences Inc. Equity Warrant’s volatility index tracking explainedQuarterly Market Review & Fast Gain Swing Alerts - newser.com

Nov 20, 2025

Nov 19, 2025

How institutional buying supports Klotho Neurosciences Inc. Equity Warrant stockBond Market & Safe Entry Point Alerts - newser.com

Nov 19, 2025

Can you recover from losses in Klotho Neurosciences Inc.Earnings Performance Report & Weekly High Return Stock Opportunities - newser.com

Nov 19, 2025

Price momentum metrics for Klotho Neurosciences Inc. explainedGlobal Markets & Free Reliable Trade Execution Plans - newser.com

Nov 19, 2025

What indicators show strength in Klotho Neurosciences Inc. Equity WarrantJuly 2025 Trends & Weekly Return Optimization Alerts - newser.com

Nov 19, 2025

What technical models suggest about Klotho Neurosciences Inc. Equity Warrant’s comebackJuly 2025 Selloffs & Weekly Momentum Picks - newser.com

Nov 19, 2025

Nov 16, 2025